Show simple item record

Anticoagulación oral en el adulto mayor frágil con fibrilación auricular

dc.contributor.authorCadena Sanabria, Miguel Oswaldospa
dc.contributor.authorPinto Saavedra, Oscar Marianospa
dc.contributor.authorContreras Valero, Juan Fernandospa
dc.contributor.authorOrtega Ramírez, Gustavo Eduardospa
dc.contributor.authorBautista Mier, Heider Alexisspa
dc.date.accessioned2020-10-27T14:19:37Z
dc.date.available2020-10-27T14:19:37Z
dc.date.issued2017-08-03
dc.identifier.issn2382-4603
dc.identifier.issn0123-7047
dc.identifier.urihttp://hdl.handle.net/20.500.12749/10006
dc.description.abstractEl envejecimiento incrementa el riesgo de trombosis y fenómenos embólicos, trae cambios fisiológicos y comorbilidades como la fibrilación auricular que hacen complejo el inicio y la seguridad de la anticoagulación. A pesar de la mayor disponibilidad de clínicas de anticoagulación y nuevos anticoagulantes orales, es bajo el porcentaje de adultos mayores que están anticoagulados aunque tengan indicación plena y ausencia de contraindicaciones.  Objetivo: Revisar las principales estrategias para predecir y disminuir el riesgo de sangrado con el empleo de anticoagulantes orales en pacientes adultos mayores frágiles. Metodología: Se realizó una búsqueda sistemática sobre estudios que evaluaran la seguridad y eficacia de anticoagulantes orales en pacientes con fibrilación auricular en adultos mayores de 65 años, y una búsqueda de estudios sobre el síndrome de fragilidad y su impacto en el adulto mayor anticoagulado. Resultados y Discusión: Se ha denominado fragilidad al porcentaje de adultos mayores que presentan un mayor deterioro de sus sistemas biológico, físico y cognitivo, conduciendo a una mayor probabilidad de desenlaces adversos en salud, discapacidad y muerte. Se han estudiado características clínicas que permiten identificar pacientes como frágiles; el fenotipo de fragilidad de Linda Fried evalúa esas características; además, existen estrategias de monitoreo de los anticoagulantes orales que deben ser conocidos para minimizar el riesgo de eventos adversos. Conclusiones: el anciano frágil presenta factores de riesgo que probablemente afectan la eficacia y seguridad de la terapia con anticoagulantes orales. Las guías clínicas existentes no proveen la suficiente evidencia y no consideran de manera multidimensional al paciente geriátrico. spa
dc.format.mimetypeapplication/pdfspa
dc.format.mimetypeApplication/vnd.openxmlformats-officedocument.wordprocessingml.documentspa
dc.language.isospaspa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/2273/2303
dc.relationHttps://revistas.unab.edu.co/index.php/medunab/article/view/2273/2724
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/article/view/2273
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceMedUNAB; Vol. 19 Núm. 3 (2017): Diciembre - Marzo de 2017: Intento Suicida, Úlceras Corneales, Anticoagulación Oral; 221-229
dc.titleAnticoagulación oral en el adulto mayor frágil con fibrilación auricular
dc.title.translatedOral anticoagulants in the frail elderly with atrial fibrillationeng
dc.title.translatedAnticoagulação oral nas pessoas idosas com fibrilhação auricularport
dc.publisher.facultyFacultad Ciencias de la Salud
dc.publisher.programPregrado Medicina
dc.type.driverinfo:eu-repo/semantics/article
dc.type.localArtículospa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.subject.keywordsAtrial fibrillation
dc.subject.keywordsFrail old man
dc.subject.keywordsAnticoagulants
dc.subject.keywordsSide effects
dc.subject.keywordsDrug-related reactions
dc.subject.keywordsGeriatrics
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.referencesSheikh A, Patel NJ, Nalluri N, Agnihotri K, Spagnola J, Patel A, Asti D, Kanotra R, Khan H, Savani C, Arora S, PatelN,ThakkarB,PatelN,PauD,BadhekaAO, Deshmukh A, Kowalski M, Viles-Gonzalez J, Paydak H. Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. Prog Cardiovasc Dis 2015; 58(2):105-116. Doi: 10.1016/j.pcad.2015.07.002
dc.relation.referencesWielochM,SjälanderA,FrykmanV,RosenqvistM, ErikssonN,SvenssonPJ.Anticoagulationcontrolin Sweden:reportsoftimeintherapeuticrange,major bleeding, and thrombo-embolic complications from the nationalqualityregistryAuriculA.EurHeartJ2011; 32(18):2282-2289. Doi: 10.1093/eurheartj/ehr134
dc.relation.referencesOlesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: Anet clinical benefit analysis using a 'real world nationwidecohortstudy.ThrombHaemost2011; 106(4):739-749. Doi: 10.1160/TH11-05-0364
dc.relation.referencesClegg A, Young J, Iliffe S, Olde-Rikkert MGM, Rockwood K. Frailty in Older People. Lancet 2013; 381(9868):752-762. Doi:10.1016/S0140-6736(12)62167-9
dc.relation.referencesRodríguez-MañasL,FriedLP.Frailtyintheclinical scenario.Lancet2014;385(9968):e7-e9.Doi: 10.1016/S0140-6736(14)61595-6
dc.relation.referencesFried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group. Frailty in Older Adults: Evidence for a Phenotype.JGerontolABiolSciMedSci2001; 56A(3):M146-156. Doi: 10.1093/gerona/56.3.M146
dc.relation.referencesGómez-MontesJF,Curcio-BorreroCL,HenaoGM. Fragilidad en ancianos Colombianos. Rev Medica.Sanitas 2012; 15(4): 8-16
dc.relation.referencesCadena-Sanabria MO, Rodríguez-Arrieta LA, Gallego-Andrade RG. Escala Identification of Seniors at Risk (ISAR):herramienta para la predicción de eventos adversos en el departamento de Urgencias. Rev Asoc Colomb Gerontol Geriatr 2013; 27(4):1887-1896
dc.relation.referencesMcCusker J, Bellavance F, Cardin S, Trépanier S, Verdon J, Ardman O. Detection of older people at increased risk of adverse health outcomes after an emergency visit: the ISARscreening tool. J Am Geriatr Soc 1999; 47(10):1229-1237. Doi: 10.1111/j.1532-5415.1999.tb05204.x
dc.relation.referencesPerera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38(2):156-162. Doi: 10.1093/ageing/afn293
dc.relation.referencesFang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, GoAS,SingerDE.Advancedage,anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141(10):745-752. Doi: 10.7326/0003-4819-141-10-200411160-00005
dc.relation.referencesFang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associatedhemorrhage:theanticoagulationandrisk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54(8):1231-1236. Doi: 10.1111/j.1532-5415.2006.00828.x
dc.relation.referencesFroom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003;120(3)526-528
dc.relation.referencesGage BF, Birman-Deych E, Kerzner R, Radford MJ, NilasenaDS,RichMW.Incidenceofintracranial hemorrhage in patients with atrial fibrillation who are prone tofall.AmJMed2005;118(6):612-617.Doi: 10.1016/j.amjmed.2005.02.022
dc.relation.referencesRosandJ,EckmanMH,KnudsenKA,SingerDE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. ArchInternMed2004;164(8):880-884.Doi: 10.1001/archinte.164.8.880
dc.relation.referencesRoldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GY. Predictive value of the HAS-BLEDand ATRIAbleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143(1):179-184. Doi: 10.1378/chest.12-0608
dc.relation.referencesApostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. PerformanceoftheHEMORR2HAGES,ATRIAand HAS-BLEDbleedingriskpredictionscoresin anticoagulatedpatientswithatrialfibrillation:The AMADEUSstudy. J Am Coll Cardiol 2013; 61(3): 386 –389. Doi: 10.1016/j.jacc.2012.10.010
dc.relation.referencesLip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P, European Heart Rhythm Association. Bleeding risk assessment and managementinatrialfibrillationpatients.Executive Summary of a Position Document from the European HeartRhythmAssociation[EHRA],endorsedbythe European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106(6):997-1011. Doi: 10.1160/TH11-10-0690
dc.relation.referencesDelaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ2007; 177(4):347-351. Doi: 10.1503/cmaj.070186
dc.relation.referencesFitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ2002; 325(7368):828-831
dc.relation.referencesSchelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin initiation in warfarin users andgastrointestinalbleedingrisk.AmJMed 2010;123(2):151-157. Doi: 10.1016/j.amjmed.2009.07.020
dc.relation.referencesApostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂score. Chest 2013; 144(5):1555-1563. Doi: 10.1378/chest.13-0054
dc.relation.referencesSingla DL, Morrill GB. Warfarin maintenance dosages in theveryelderly.AmJHealthSystPharm2005;62 (10):1062-1066
dc.relation.referencesVogel T, Geny B, Kaltenbach G, Lang PO. Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants. Rev Med Interne2015;36(1):22-30.Doi:10.1016/j.revmed. 2014.08.005
dc.relation.referencesWang Y, Bajorek B. New oral anticoagulants in practice: pharmacologicalandpracticalconsiderations.AmJ Cardiovasc Drugs 2014; 14(3):175-189. Doi: 10.1007/ s40256-013-0061-0
dc.relation.referencesHeidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European HeartRhythmAssociation.EuropeanHeartRhythm AssociationPracticalGuideontheuseofneworal anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15(5):625-651. Doi: 10.1093/ europace/ eut083
dc.relation.referencesGosselinRC,DwyreDM,DagerWE.Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 2013; 47(12):1635-1640. Doi: 10.1177/1060028013509074
dc.relation.referencesStangier J, Feuring M. Using the HEMOCLOT direct thrombininhibitorassaytodetermineplasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23(2):138-143.Doi:10.1097/MBC. 0b013e32834f1b0c
dc.relation.referencesGouin-Thibault I, Flaujac C, Delavenne X, Quenet S, HorellouMH,LaporteS,SiguretV,LecompteT. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. Amulticentre French GEHT study. Thromb Haemost 2014; 111(2):240-248. Doi: 10.1160/TH13-06-0470
dc.relation.referencesSardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62(5):857-864. Doi: 10.1111/jgs.12799
dc.relation.referencesVeiga-FernándezF,Malfeito-JiménezMDR,Barros-Cerviño SM, Magariños-Losada MDM. La anticoagulación oral en el anciano con fibrilación auricular no valvular. Rev Esp Geriatr Gerontol 2015; 50(3):134-142. Doi:10.1016/ j.regg.2015.01.005
dc.relation.referencesEdholmK,RagleN,RondinaMT.Antithrombotic management of atrial fibrillation in the elderly. Med Clin NorthAm2015;99(2):417-430.Doi:10.1016/j.mcna. 2014.11.012
dc.relation.referencesGranziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc 2015; 16(5):358-64. Doi: 10.1016/j.jamda.2014.12.008
dc.relation.referencesLubitz SA, Bauer KA, Benjamin EJ, Besdine RW, Forman DE, Gurol ME, Reddy VY, Singer DE. Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar. J Am Geriatr Soc 2013; 61(10):1798-803. Doi: 10.1111/jgs.12456
dc.relation.referencesHylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation2007;115(21):2689-2696.Doi:10.1161/ CIRCULATIONAHA.106.653048
dc.relation.referencesZarraga IG, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. J Am Geriatr Soc 2013; 61(1):143-150. Doi: 10.1111/jgs.12042
dc.relation.referencesGranger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patientswithatrialfibrillation.NEnglJMed2011; 365(11):981-992. Doi: 10.1056/NEJMoa1107039
dc.contributor.cvlacCadena Sanabria, Miguel Oswaldo [0001339250]
dc.contributor.cvlacPinto Saavedra, Oscar Mariano [0001692640]
dc.contributor.cvlacContreras Valero, Juan Fernando [0000121483]
dc.contributor.cvlacOrtega Ramírez, Gustavo Eduardo [0001482931]
dc.contributor.googlescholarCadena Sanabria, Miguel Oswaldo [jQUx5WcAAAAJ&hl=es&oi=ao]
dc.contributor.googlescholarPinto Saavedra, Oscar Mariano [DdZsdW4AAAAJ&hl=es&oi=ao]
dc.contributor.orcidCadena Sanabria, Miguel Oswaldo [0000-0001-9807-3029]
dc.contributor.orcidPinto Saavedra, Oscar Mariano [0000-0003-1396-0759]
dc.subject.lembCiencias medicas
dc.subject.lembMedicina
dc.identifier.repourlrepourl:https://repository.unab.edu.co
dc.description.abstractenglishAging increases the risk of thrombosis and embolic phenomena. It also brings physiological changes, and comorbidities such as atrial fibrillation that makes complex the onset and safety of anti-clotting. Despite the greater availability of anti-clotting clinics and new oral anticoagulants, the percentage of elderly who are anticoagulated is low, even though they have indications and no contraindications. Objective: To review the main strategies to predict and reduce the risk of bleeding with the use of oral anti-clotting in fragile elderly patients. Methodology: A systematic search was conducted on studies evaluating the safety and efficacy of oral anticoagulants in patients with atrial fibrillation in adults older than 65 years, and a search for studies on the frailty syndrome and its impact on the elderly anticoagulated. Results and Discussion: Fragility has been termed to the percentage of elderly who were diagnosed with a greater deterioration of their biological, physical and cognitive systems, leading to a greater probability of adverse outcomes in health, disability and death. Some clinical features have been studied to identify patients as fragile; Linda Fried's frailty phenotype evaluates these characteristics; furthermore, there are strategies for monitoring oral anticoagulants that should be known to reduce the risk of adverse events. Conclusions: The frail elderly has some risk factors that are likely to affect the efficacy and safety of oral anti-clotting therapy. Existing clinical guidelines do not provide enough evidence and do not consider the elderly patient in a multidimensional manner.eng
dc.subject.proposalFibrilación atrial
dc.subject.proposalAnciano frágil
dc.subject.proposalAnticoagulantes
dc.subject.proposalEfectos colaterales
dc.subject.proposalReacciones relacionados con medicamentos
dc.subject.proposalGeriatría
dc.identifier.doi10.29375/01237047.2273
dc.type.redcolhttp://purl.org/redcol/resource_type/ART
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*


Files in this item

Thumbnail
Name:
2017_Anticoagulación_oral_en_e ...
Size:
1.087Mb
Format:
PDF
Description:
Articulo
View/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 2.5 Colombia